openPR Logo
Press release

Neuroendocrine Carcinoma Market - Will Reflect Significant Growth Prospects during 2014-2020.

09-15-2017 07:07 AM CET | Health & Medicine

Press release from: TMR - PH

Neuroendocrine Carcinoma Market - Will Reflect Significant

A neuroendocrine tumor is a kind of tumor that begins in the hormone producing cells of the neuroendocrine system that is made up of the endocrine system and nervous system. Hormones producing neuroendocrine cells have a structure similar to neurons and produce hormones like endocrine cells. These cells are found throughout the body in organs such as intestines, kidneys, lungs and stomach and perform functions such as controlling the speed of food through gastrointestinal tract and air and blood flow through the lungs. Neuroendocrine tumor is a rare malignant disorder that accounts for nearly one percent of all malignant disorders. Neuroendocrine carcinomas account for nearly 60% of all neuroendocrine tumor cases and are characterized as their origin in different locations throughout the body including lungs, gastrointestinal tract and brain. Some common symptoms associated with neuroendocrine carcinoma are hyperglycemia, hypoglycemia, weight loss, loss of appetite, headache, anxiety, gastric ulcer, unusual bleeding, jaundice, diarrhea, fever and persistent in specific area.

The treatment options for neuroendocrine carcinoma include surgery, radiation therapy and chemotherapy. Chemotherapy involves the use of drugs to kill cancerous cells by inhibiting the cells ability to grow and divide. Streptozocin (Zanosar) and 5-fluorouracil (Adrucil, 5-FU) are some drugs that are used to treat neuroendocrine carcinomas. Continuous efforts by major pharmaceuticals in order to develop targeted therapy have been contributing in the growth of neuroendocrine carcinomas market. Everolimus (Afinitor) and sunitinib (Sutent) are two major targeted drugs that are being used for treating neuroendocrine carcinomas.

Browse Market Research Report @ http://www.transparencymarketresearch.com/neuroendocrine-carcinoma-market.html

Afinitor was introduced by Novartis AG in 2009 for the treatment of advanced renal cell carcinoma. This drug is useful when sunitinib or sorafenib fail to treat the renal cell carcinoma. Sutent is a brand developed by Pfizer Ltd. and is used to treat advanced renal cell carcinoma and gastrointestinal stromal tumor. F. Hoffmann-La Roche Ltd., BioSynthema, Inc., Genentech Inc. and Callisto Pharmaceuticals Pvt. Ltd. are some major companies that are striving to develop drugs for treating various neuroendocrine carcinomas. Avastin, Atiprimod and Lutathera are among other molecules that are currently being studied for their therapeutic efficacy in the treatment of neuroendocrine carcinomas.

Geographically, the market for neuroendocrine carcinoma has been segmented into North America, Europe, Asia Pacific and Rest of the World (RoW). United States and Canada are the two major markets in North America region. North America represented the largest market for neuroendocrine carcinoma in 2013, with a largest market share in terms of revenue (USD Million). According to sources from Cancer.Net, nearly 8,000 people are diagnosed with neuroendocrine tumors every year in the United States. Many of the key players operating in this market space are based out of U.S and thus consider North America as their primary market for product launch and investment.

Make an Enquiry @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2970

Also, the well established healthcare infrastructure and reimbursement scenario are among the major factors responsible for North America’s leading position in neuroendocrine carcinoma market. Europe accounted for the second largest market in 2013, followed by Asia Pacific and Rest of the World (RoW). Growing incidence of neuroendocrine carcinoma in Asia Pacific along with the improving economic scenario is likely to play a key role in driving the market growth in the region.

F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Ltd., Eli Lilly & Company, Amgen, Inc., Ispen SA, Callisto Pharmaceuticals Pvt. Ltd., Bristol-Myers Squibb, Teva Pharmaceuticals, Ltd. and Biosynthema, Inc. are among others operating in the Neuroendocrine carcinoma market.

About Us:-

Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.

We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us:-

Transparency Market Research

90 State Street, Suite 700, Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Neuroendocrine Carcinoma Market - Will Reflect Significant Growth Prospects during 2014-2020. here

News-ID: 718414 • Views:

More Releases from TMR - PH

Rubella Testing Market- Technological breakthroughs, Value chain and stakeholder analysis by 2024.
Rubella Testing Market- Technological breakthroughs, Value chain and stakeholder …
Rubella or German measles is a serious condition (disease) caused by the infection of rubivirus (genus). Sometimes rubella when passed from pregnant mother to her baby then it is termed as congenital rubella. Rubella is a contagious disease and can spread through air or close contact between patient and a healthy individual. Signs and symptom of rubella include fever, headache, inflammation of the eyes and muscle or joint pain. Culture test
Proteins in Oncology Market Research Report by Regional Analysis - North America, Europe, Asia Pacific, Latin America, Middle East & Africa : forecast 2023
Proteins in Oncology Market Research Report by Regional Analysis - North America …
Global Protein in Oncology Market Oncology is the branch of medical science dealing with cancer research and treatment. There are several research facilities and universities identifying unique proteins in oncology for developing diagnostics. Several studies are underway to discover new proteins that play a role in cancer. Currently there are a number of companies and/or their collaborators engaged in developing several protein drugs in cancer. Surgical treatments and radiation therapy, though
Systemic Antiviral Pharmaceuticals Market Research Report by Regional Analysis - North America, Europe, Asia Pacific, Latin America, Middle East & Africa : forecast 2023
Systemic Antiviral Pharmaceuticals Market Research Report by Regional Analysis - …
Global Systemic Antiviral Pharmaceuticals Market Antiviral drugs are a class of medication that inhibits the development of infection causing viruses. Like antibiotics, specific antiviral drugs are used against specific viruses. As viruses share most of the metabolic processes with the host cell, it is difficult to commercialize new medications that are selective in action. The presently available antiviral agents either act as DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, immunomodulators,
Anti-Obesity Drugs Market Research Report by Regional Analysis - North America, Europe, Asia Pacific, Latin America, Middle East & Africa : forecast 2024
Anti-Obesity Drugs Market Research Report by Regional Analysis - North America, …
Global Anti-Obesity Drugs Market: Overview The World Health Organization reveals that global obesity has more than doubled since 1980, with over 1.9 billion adults overweight in 2014, of which, more than 600 million were obese. Percentage-wise, an estimated 39% of adults were overweight and 13% were obese in 2014. An additional 42 million children below the age of five were found to be overweight or obese in 2013. Based on two

All 5 Releases


More Releases for Neuroendocrine

Neuroendocrine Tumor Treatment Market – Forecast to 2026
According to a new market research report published by Global Market Estimates, the Global Neuroendocrine Tumor Treatment Market is projected to grow from USD 1.8 billion in 2021 to USD 2.1 billion by 2026 at a CAGR value of 5.7% between 2021 to 2026. High prevalence of neuropsychiatric malignancy, awareness regarding early cancer diagnosis, and an increasing number of government initiatives, the neuroendocrine tumor therapy market is expected to rise
Neuroendocrine Carcinoma Market Size - Forecasts to 2026
The findings reviewed by GME stated that the Global Neuroendocrine Carcinoma Market will expand with a CAGR value of 10.6 percent from 2021 to 2026. Owing to a rise in the prevalence of neuroendocrine tumors (NETs) across the globe, the global neuroendocrine carcinoma market will grow rapidly during 2021-2026 forecast period. Browse the Report @ https://www.globalmarketestimates.com/market-report/global-neuroendocrine-carcinoma-market-3109 By Site (Gastrointestinal, Lung, Brain, Pancreas, and Others), By Therapy (Surgery, Radiation Therapy, and Chemotherapy), By
Neuroendocrine Cancer Market: Rising Prevalence of Neuroendocrine Cancer and Gro …
The market report titled ‘Global Neuroendocrine Cancer Market - Size, Share and Forecast (2019 - 2026)’ produced by DataM Intelligence analyses the industry dynamics in this competitive space to provide a comprehensive analysis of the market opportunities. Neuroendocrine Cancer Market Segmentation Analysis Total Neuroendocrine Cancer Studies: 2499 By Drug Type Everolimus Sunitinib Malate Lanreotide Octreotide Others Sunitinib (Sutent) and Everolimus (Afinitor) are two major targeted drugs that are being used for the treatment of
Neuroendocrine Carcinoma Market Analysis & Key Trends 2020
A neuroendocrine tumor is a kind of tumor that begins in the hormone producing cells of the neuroendocrine system that is made up of the endocrine system and nervous system. Hormones producing neuroendocrine cells have a structure similar to neurons and produce hormones like endocrine cells. These cells are found throughout the body in organs such as intestines, kidneys, lungs and stomach and perform functions such as controlling the speed
Neuroendocrine Tumors Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors - Pipeline Review, H1 2017, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape. Neuroendocrine tumor begins in the hormone-producing cells of the body's neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part
Neuroendocrine Tumors Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors - Pipeline Review, H1 2017, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape. Neuroendocrine tumor begins in the hormone-producing cells of the body's neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part